United States Biotechnology & Medical Research

Constellation Pharmaceuticals Inc (CNST)

Track

Track

Constellation Pharmaceuticals Inc. experienced multiple insider transactions during early 2021. Chief Financial Officer Emma Reeve and other stakeholders executed several planned sales between December 2020 and February 2021. The most recent activity occurred on February 22, 2021. No significant trading has been reported by company insiders within the last three months.
Ticker: CNST Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Reeve Emma Chief Financial Officer Officer
Transaction date
Planned sale
Price
477.23
Quantity 21,166 +6.0%
Value US$4,024,204
Reeve Emma Chief Financial Officer Officer
Transaction date
Planned sale
Price
338.99
Quantity 39,714 -15.1%
Value US$4,563,093
Reeve Emma Chief Financial Officer Officer
Transaction date
Planned sale
Price
299.11
Quantity 56,978 -21.3%
Value US$2,044,120
Reeve Emma Chief Financial Officer Officer
Transaction date
Planned sale
Price
37.56
Quantity 410 -100.0%
Value US$15,398
3.9
COLUMN GROUP L P Large shareholder
Transaction date
Sale
Price
36.95
Quantity 10,000 -9.2%
Value US$369,503
3.9
COLUMN GROUP L P Large shareholder
Transaction date
Sale
Price
36.95
Quantity 10,000 -9.2%
Value US$369,503
Valentine Karen See Remarks Officer
Transaction date
Planned sale
Price
35.11
Quantity 7,203 -100.0%
Value US$252,889
Valentine Karen See Remarks Officer
Transaction date
Planned sale
Price
33.69
Quantity 1,227 -14.6%
Value US$41,342
Valentine Karen See Remarks Officer
Transaction date
Planned sale
Price
33.08
Quantity 8,773 -51.0%
Value US$290,232
2.2
GOLDSMITH MARK A Non-Executive Director Large shareholder
Transaction date
Planned sale
Price
35.02
Quantity 4,020 -2.8%
Value US$140,769
Reeve Emma Chief Financial Officer Officer
Transaction date
Planned sale
Price
35.11
Quantity 5,720 -100.0%
Value US$200,805
Reeve Emma Chief Financial Officer Officer
Transaction date
Planned sale
Price
38.35
Quantity 233 -100.0%
Value US$8,936
Reeve Emma Chief Financial Officer Officer
Transaction date
Planned sale
Price
37.67
Quantity 144 -38.2%
Value US$5,424
Reeve Emma Chief Financial Officer Officer
Transaction date
Planned sale
Price
36.59
Quantity 212 -36.0%
Value US$7,757
Raythatha Jigar See Remarks Executive Director
Transaction date
Planned sale
Price
50.17
Quantity 9,209 -38.1%
Value US$461,981
1.6
Senderowicz Adrian Chief Medical Officer Officer
Transaction date
Planned sale
Price
50.18
Quantity 9,357 -37.1%
Value US$469,488
2.2
GOLDSMITH MARK A Non-Executive Director Large shareholder
Transaction date
Planned sale
Price
50.05
Quantity 4,225 -2.9%
Value US$211,474
Audia James E Non-Executive Director
Transaction date
Planned sale
Price
50.10
Quantity 6,100 -19.3%
Value US$305,622
Raythatha Jigar See Remarks Executive Director
Transaction date
Planned sale
Price
50.00
Quantity 26 -0.2%
Value US$1,300
2.2
GOLDSMITH MARK A Non-Executive Director Large shareholder
Transaction date
Planned sale
Price
50.00
Quantity 100 -0.1%
Value US$5,000
Reeve Emma Chief Financial Officer Officer
Transaction date
Planned sale
Price
49.53
Quantity 16,062 -100.0%
Value US$795,623
Reeve Emma Chief Financial Officer Officer
Transaction date
Planned sale
Price
49.53
Quantity 12,741 -100.0%
Value US$631,055
Valentine Karen See Remarks
Transaction date
Planned sale
Price
40.10
Quantity 12,566 -100.0%
Value US$503,897
Audia James E
Transaction date
Planned sale
Price
45.15
Quantity 7,500 -19.2%
Value US$338,600
2.2
GOLDSMITH MARK A
Transaction date
Planned sale
Price
45.06
Quantity 11,463 -7.4%
Value US$516,545
Trojer Patrick Chief Scientific Officer
Transaction date
Planned sale
Price
45.16
Quantity 10,000 -100.0%
Value US$451,553
Valentine Karen See Remarks
Transaction date
Planned sale
Price
40.01
Quantity 4,744 -100.0%
Value US$189,817
2.2
GOLDSMITH MARK A
Transaction date
Planned sale
Price
40.01
Quantity 3,145 -2.2%
Value US$125,824
Valentine Karen See Remarks
Transaction date
Planned sale
Price
40.13
Quantity 400 -100.0%
Value US$16,052
2.2
GOLDSMITH MARK A
Transaction date
Planned sale
Price
40.12
Quantity 400 -0.3%
Value US$16,049
Valentine Karen See Remarks
Transaction date
Planned sale
Price
33.65
Quantity 789 -100.0%
Value US$26,550
Valentine Karen See Remarks
Transaction date
Planned sale
Price
35.19
Quantity 2,300 -100.0%
Value US$80,939
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
35.29
Quantity 760 -100.0%
Value US$26,820
Valentine Karen See Remarks
Transaction date
Planned sale
Price
34.09
Quantity 1,043 -100.0%
Value US$35,552
Valentine Karen See Remarks
Transaction date
Planned sale
Price
33.29
Quantity 1,955 -65.2%
Value US$65,085
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
35.20
Quantity 1,225 -100.0%
Value US$43,123
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
35.02
Quantity 589 -100.0%
Value US$20,626
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
35.02
Quantity 111 -100.0%
Value US$3,887
Valentine Karen See Remarks
Transaction date
Planned sale
Price
35.02
Quantity 635 -100.0%
Value US$22,236
3.9
COLUMN GROUP L P General Partner Large shareholder
Transaction date
Purchase
Price
23.15
Quantity 5,539 +0.1%
Value US$128,228
3.9
COLUMN GROUP L P General Partner Large shareholder
Transaction date
Purchase
Price
23.15
Quantity 5,539 +0.1%
Value US$128,228
3.9
COLUMN GROUP L P General Partner Large shareholder
Transaction date
Purchase
Price
22.38
Quantity 36,135 +0.6%
Value US$808,701
3.9
COLUMN GROUP L P General Partner Large shareholder
Transaction date
Purchase
Price
22.38
Quantity 36,135 +0.6%
Value US$808,701
Valentine Karen See Remarks
Transaction date
Planned sale
Price
32.92
Quantity 130 -100.0%
Value US$4,279
Valentine Karen See Remarks
Transaction date
Planned sale
Price
32.08
Quantity 335 -72.0%
Value US$10,746
Valentine Karen See Remarks
Transaction date
Planned sale
Price
31.17
Quantity 152 -24.6%
Value US$4,738
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
35.06
Quantity 5,521 -100.0%
Value US$193,539
Valentine Karen See Remarks
Transaction date
Planned sale
Price
35.07
Quantity 4,473 -100.0%
Value US$156,859
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
35.02
Quantity 1,103 -100.0%
Value US$38,624
Valentine Karen See Remarks
Transaction date
Planned sale
Price
35.02
Quantity 1,500 -100.0%
Value US$52,527
Valentine Karen See Remarks
Transaction date
Sale
Price
35.03
Quantity 8,550 -100.0%
Value US$299,506
Reeve Emma Chief Financial Officer
Transaction date
Sale
Price
35.04
Quantity 1,430 -100.0%
Value US$50,107
Reeve Emma Chief Financial Officer
Transaction date
Sale
Price
35.04
Quantity 7,212 -100.0%
Value US$252,708
Valentine Karen See Remarks
Transaction date
Sale
Price
33.51
Quantity 14,096 -100.0%
Value US$472,357
Reeve Emma Chief Financial Officer
Transaction date
Sale
Price
35.00
Quantity 200 -100.0%
Value US$7,000
Venrock Healthcare Capital Partners III, L.P. Large shareholder
Transaction date
Purchase
Price
34.50
Quantity 400,000 +11.1%
Value US$13,800,000
EVNIN ANTHONY B Non-Executive Director
Transaction date
Purchase
Price
34.50
Quantity 400,000 +7.5%
Value US$13,800,000
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
30.84
Quantity 726 -100.0%
Value US$22,390
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
29.75
Quantity 15,740 -95.6%
Value US$468,260
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
20.01
Quantity 11,976 -42.1%
Value US$239,631
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
19.20
Quantity 6,188 -17.9%
Value US$118,839
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
18.40
Quantity 24,264 -41.2%
Value US$446,518
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
17.59
Quantity 4,158 -6.6%
Value US$73,158
Reeve Emma Chief Financial Officer
Transaction date
Planned sale
Price
16.31
Quantity 2,574 -3.9%
Value US$41,979
Raythatha Jigar See Remarks
Transaction date
Planned sale
Price
36.01
Quantity 350 -2.3%
Value US$12,602
Raythatha Jigar See Remarks
Transaction date
Planned sale
Price
35.23
Quantity 20,200 -56.9%
Value US$711,579
Raythatha Jigar See Remarks
Transaction date
Planned sale
Price
31.32
Quantity 12,095 -25.4%
Value US$378,795
Raythatha Jigar See Remarks
Transaction date
Planned sale
Price
30.19
Quantity 29,005 -37.9%
Value US$875,528
Raythatha Jigar See Remarks
Transaction date
Planned sale
Price
25.06
Quantity 20,550 -21.2%
Value US$514,952
Raythatha Jigar See Remarks
Transaction date
Planned sale
Price
21.20
Quantity 3,170 -3.2%
Value US$67,198
Raythatha Jigar See Remarks
Transaction date
Planned sale
Price
20.18
Quantity 17,380 -14.8%
Value US$350,727
Audia James E
Transaction date
Planned sale
Price
19.11
Quantity 7,500 -16.1%
Value US$143,356
Audia James E
Transaction date
Planned sale
Price
18.58
Quantity 10,500 -18.4%
Value US$195,076
Audia James E
Transaction date
Planned sale
Price
17.55
Quantity 4,500 -7.3%
Value US$78,978
Senderowicz Adrian Chief Medical Officer
Transaction date
Planned sale
Price
35.11
Quantity 5,451 -25.5%
Value US$191,394
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2021-02-23 2021-02-22 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
21,166 +6.0%
477.23
US$4,024,204 		21,166 +6.0% 477.23 US$4,024,204
2021-02-23 2021-02-19 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
39,714 -15.1%
338.99
US$4,563,093 		39,714 -15.1% 338.99 US$4,563,093
2021-02-19 2021-02-18 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
56,978 -21.3%
299.11
US$2,044,120 		56,978 -21.3% 299.11 US$2,044,120
2021-02-19 2021-02-17 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
410 -100.0%
37.56
US$15,398 		410 -100.0% 37.56 US$15,398
2021-02-19 2021-02-17 S Sale
3.9
COLUMN GROUP L P
Large shareholder
10,000 -9.2%
36.95
US$369,503 		10,000 -9.2% 36.95 US$369,503
2021-02-19 2021-02-17 S Sale
3.9
COLUMN GROUP L P
Large shareholder
10,000 -9.2%
36.95
US$369,503 		10,000 -9.2% 36.95 US$369,503
2021-01-20 2021-01-19 PlS Planned sale
Valentine Karen

See Remarks

Officer
7,203 -100.0%
35.11
US$252,889 		7,203 -100.0% 35.11 US$252,889
2021-01-20 2021-01-19 PlS Planned sale
Valentine Karen

See Remarks

Officer
1,227 -14.6%
33.69
US$41,342 		1,227 -14.6% 33.69 US$41,342
2021-01-20 2021-01-19 PlS Planned sale
Valentine Karen

See Remarks

Officer
8,773 -51.0%
33.08
US$290,232 		8,773 -51.0% 33.08 US$290,232
2020-12-28 2020-12-21 PlS Planned sale
2.2
GOLDSMITH MARK A
Non-Executive Director Large shareholder
4,020 -2.8%
35.02
US$140,769 		4,020 -2.8% 35.02 US$140,769
2020-12-22 2020-12-21 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
5,720 -100.0%
35.11
US$200,805 		5,720 -100.0% 35.11 US$200,805
2020-06-10 2020-06-08 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
233 -100.0%
38.35
US$8,936 		233 -100.0% 38.35 US$8,936
2020-06-10 2020-06-08 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
144 -38.2%
37.67
US$5,424 		144 -38.2% 37.67 US$5,424
2020-06-10 2020-06-08 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
212 -36.0%
36.59
US$7,757 		212 -36.0% 36.59 US$7,757
2020-05-13 2020-05-12 PlS Planned sale
Raythatha Jigar

See Remarks

Executive Director
9,209 -38.1%
50.17
US$461,981 		9,209 -38.1% 50.17 US$461,981
2020-05-13 2020-05-12 PlS Planned sale
1.6
Senderowicz Adrian

Chief Medical Officer

Officer
9,357 -37.1%
50.18
US$469,488 		9,357 -37.1% 50.18 US$469,488
2020-05-13 2020-05-12 PlS Planned sale
2.2
GOLDSMITH MARK A
Non-Executive Director Large shareholder
4,225 -2.9%
50.05
US$211,474 		4,225 -2.9% 50.05 US$211,474
2020-05-13 2020-05-12 PlS Planned sale
Audia James E
Non-Executive Director
6,100 -19.3%
50.10
US$305,622 		6,100 -19.3% 50.10 US$305,622
2020-05-13 2020-05-11 PlS Planned sale
Raythatha Jigar

See Remarks

Executive Director
26 -0.2%
50.00
US$1,300 		26 -0.2% 50.00 US$1,300
2020-05-13 2020-05-11 PlS Planned sale
2.2
GOLDSMITH MARK A
Non-Executive Director Large shareholder
100 -0.1%
50.00
US$5,000 		100 -0.1% 50.00 US$5,000
2020-05-12 2020-05-11 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
16,062 -100.0%
49.53
US$795,623 		16,062 -100.0% 49.53 US$795,623
2020-05-12 2020-05-08 PlS Planned sale
Reeve Emma

Chief Financial Officer

Officer
12,741 -100.0%
49.53
US$631,055 		12,741 -100.0% 49.53 US$631,055
2020-05-07 2020-05-06 PlS Planned sale
Valentine Karen

See Remarks
12,566 -100.0%
40.10
US$503,897 		12,566 -100.0% 40.10 US$503,897
2020-05-07 2020-05-06 PlS Planned sale
Audia James E
7,500 -19.2%
45.15
US$338,600 		7,500 -19.2% 45.15 US$338,600
2020-05-07 2020-05-06 PlS Planned sale
2.2
GOLDSMITH MARK A
11,463 -7.4%
45.06
US$516,545 		11,463 -7.4% 45.06 US$516,545
2020-05-07 2020-05-06 PlS Planned sale
Trojer Patrick

Chief Scientific Officer
10,000 -100.0%
45.16
US$451,553 		10,000 -100.0% 45.16 US$451,553
2020-05-07 2020-05-05 PlS Planned sale
Valentine Karen

See Remarks
4,744 -100.0%
40.01
US$189,817 		4,744 -100.0% 40.01 US$189,817
2020-05-07 2020-05-05 PlS Planned sale
2.2
GOLDSMITH MARK A
3,145 -2.2%
40.01
US$125,824 		3,145 -2.2% 40.01 US$125,824
2020-04-29 2020-04-27 PlS Planned sale
Valentine Karen

See Remarks
400 -100.0%
40.13
US$16,052 		400 -100.0% 40.13 US$16,052
2020-04-29 2020-04-27 PlS Planned sale
2.2
GOLDSMITH MARK A
400 -0.3%
40.12
US$16,049 		400 -0.3% 40.12 US$16,049
2020-04-22 2020-04-20 PlS Planned sale
Valentine Karen

See Remarks
789 -100.0%
33.65
US$26,550 		789 -100.0% 33.65 US$26,550
2020-04-20 2020-04-17 PlS Planned sale
Valentine Karen

See Remarks
2,300 -100.0%
35.19
US$80,939 		2,300 -100.0% 35.19 US$80,939
2020-04-20 2020-04-17 PlS Planned sale
Reeve Emma

Chief Financial Officer
760 -100.0%
35.29
US$26,820 		760 -100.0% 35.29 US$26,820
2020-04-20 2020-04-16 PlS Planned sale
Valentine Karen

See Remarks
1,043 -100.0%
34.09
US$35,552 		1,043 -100.0% 34.09 US$35,552
2020-04-20 2020-04-16 PlS Planned sale
Valentine Karen

See Remarks
1,955 -65.2%
33.29
US$65,085 		1,955 -65.2% 33.29 US$65,085
2020-04-16 2020-04-14 PlS Planned sale
Reeve Emma

Chief Financial Officer
1,225 -100.0%
35.20
US$43,123 		1,225 -100.0% 35.20 US$43,123
2020-04-13 2020-04-09 PlS Planned sale
Reeve Emma

Chief Financial Officer
589 -100.0%
35.02
US$20,626 		589 -100.0% 35.02 US$20,626
2020-04-13 2020-04-09 PlS Planned sale
Reeve Emma

Chief Financial Officer
111 -100.0%
35.02
US$3,887 		111 -100.0% 35.02 US$3,887
2020-04-13 2020-04-09 PlS Planned sale
Valentine Karen

See Remarks
635 -100.0%
35.02
US$22,236 		635 -100.0% 35.02 US$22,236
2020-03-23 2020-03-20 B Purchase
3.9
COLUMN GROUP L P

General Partner

Large shareholder
5,539 +0.1%
23.15
US$128,228 		5,539 +0.1% 23.15 US$128,228
2020-03-23 2020-03-20 B Purchase
3.9
COLUMN GROUP L P

General Partner

Large shareholder
5,539 +0.1%
23.15
US$128,228 		5,539 +0.1% 23.15 US$128,228
2020-03-23 2020-03-19 B Purchase
3.9
COLUMN GROUP L P

General Partner

Large shareholder
36,135 +0.6%
22.38
US$808,701 		36,135 +0.6% 22.38 US$808,701
2020-03-23 2020-03-19 B Purchase
3.9
COLUMN GROUP L P

General Partner

Large shareholder
36,135 +0.6%
22.38
US$808,701 		36,135 +0.6% 22.38 US$808,701
2020-03-11 2020-03-09 PlS Planned sale
Valentine Karen

See Remarks
130 -100.0%
32.92
US$4,279 		130 -100.0% 32.92 US$4,279
2020-03-11 2020-03-09 PlS Planned sale
Valentine Karen

See Remarks
335 -72.0%
32.08
US$10,746 		335 -72.0% 32.08 US$10,746
2020-03-11 2020-03-09 PlS Planned sale
Valentine Karen

See Remarks
152 -24.6%
31.17
US$4,738 		152 -24.6% 31.17 US$4,738
2020-02-14 2020-02-13 PlS Planned sale
Reeve Emma

Chief Financial Officer
5,521 -100.0%
35.06
US$193,539 		5,521 -100.0% 35.06 US$193,539
2020-02-14 2020-02-13 PlS Planned sale
Valentine Karen

See Remarks
4,473 -100.0%
35.07
US$156,859 		4,473 -100.0% 35.07 US$156,859
2020-02-14 2020-02-12 PlS Planned sale
Reeve Emma

Chief Financial Officer
1,103 -100.0%
35.02
US$38,624 		1,103 -100.0% 35.02 US$38,624
2020-02-14 2020-02-12 PlS Planned sale
Valentine Karen

See Remarks
1,500 -100.0%
35.02
US$52,527 		1,500 -100.0% 35.02 US$52,527
2020-02-12 2020-02-11 S Sale
Valentine Karen

See Remarks
8,550 -100.0%
35.03
US$299,506 		8,550 -100.0% 35.03 US$299,506
2020-02-12 2020-02-11 S Sale
Reeve Emma

Chief Financial Officer
1,430 -100.0%
35.04
US$50,107 		1,430 -100.0% 35.04 US$50,107
2020-02-12 2020-02-11 S Sale
Reeve Emma

Chief Financial Officer
7,212 -100.0%
35.04
US$252,708 		7,212 -100.0% 35.04 US$252,708
2020-02-12 2020-02-10 S Sale
Valentine Karen

See Remarks
14,096 -100.0%
33.51
US$472,357 		14,096 -100.0% 33.51 US$472,357
2020-02-12 2020-02-10 S Sale
Reeve Emma

Chief Financial Officer
200 -100.0%
35.00
US$7,000 		200 -100.0% 35.00 US$7,000
2019-12-16 2019-12-13 B Purchase Venrock Healthcare Capital Partners III, L.P. Large shareholder
400,000 +11.1%
34.50
US$13,800,000 		400,000 +11.1% 34.50 US$13,800,000
2019-12-16 2019-12-13 B Purchase EVNIN ANTHONY B Non-Executive Director
400,000 +7.5%
34.50
US$13,800,000 		400,000 +7.5% 34.50 US$13,800,000
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
726 -100.0%
30.84
US$22,390 		726 -100.0% 30.84 US$22,390
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
15,740 -95.6%
29.75
US$468,260 		15,740 -95.6% 29.75 US$468,260
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
11,976 -42.1%
20.01
US$239,631 		11,976 -42.1% 20.01 US$239,631
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
6,188 -17.9%
19.20
US$118,839 		6,188 -17.9% 19.20 US$118,839
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
24,264 -41.2%
18.40
US$446,518 		24,264 -41.2% 18.40 US$446,518
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
4,158 -6.6%
17.59
US$73,158 		4,158 -6.6% 17.59 US$73,158
2019-11-08 2019-11-06 PlS Planned sale Reeve Emma

Chief Financial Officer
2,574 -3.9%
16.31
US$41,979 		2,574 -3.9% 16.31 US$41,979
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
350 -2.3%
36.01
US$12,602 		350 -2.3% 36.01 US$12,602
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
20,200 -56.9%
35.23
US$711,579 		20,200 -56.9% 35.23 US$711,579
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
12,095 -25.4%
31.32
US$378,795 		12,095 -25.4% 31.32 US$378,795
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
29,005 -37.9%
30.19
US$875,528 		29,005 -37.9% 30.19 US$875,528
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
20,550 -21.2%
25.06
US$514,952 		20,550 -21.2% 25.06 US$514,952
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
3,170 -3.2%
21.20
US$67,198 		3,170 -3.2% 21.20 US$67,198
2019-11-08 2019-11-06 PlS Planned sale Raythatha Jigar

See Remarks
17,380 -14.8%
20.18
US$350,727 		17,380 -14.8% 20.18 US$350,727
2019-11-08 2019-11-06 PlS Planned sale Audia James E
7,500 -16.1%
19.11
US$143,356 		7,500 -16.1% 19.11 US$143,356
2019-11-08 2019-11-06 PlS Planned sale Audia James E
10,500 -18.4%
18.58
US$195,076 		10,500 -18.4% 18.58 US$195,076
2019-11-08 2019-11-06 PlS Planned sale Audia James E
4,500 -7.3%
17.55
US$78,978 		4,500 -7.3% 17.55 US$78,978
2019-11-08 2019-11-06 PlS Planned sale Senderowicz Adrian

Chief Medical Officer
5,451 -25.5%
35.11
US$191,394 		5,451 -25.5% 35.11 US$191,394
Explore more

More insider trading research around Constellation Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America